Relative Intelligence · Life Sciences Tools

How Illumina (ILMN) compares with the whole market and its popular alternatives
Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on ILMN alone. It places ILMN (Illumina, Inc.) against 20+ popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where ILMN stands in the market, and of the alternatives worth a closer look.
Period covered: ILMN's full trading record, from July 2000 through September 2026. The crash tests reach back to 2000 using older funds and the S&P 500. All returns include reinvested dividends. Data as of October 20, 2026.
Data as of October 20, 2026. Full tables and charts read best on a larger screen.
On this page12 sections
Key findings
- Right nowOver the past 6 months, ILMN rose 102% against 9.1% for the S&P 500 and 11.2% for the Nasdaq 100. That said, the slide is ILMN's own: it is 47.5% below its high, against 1.3% for the S&P 500. At a glance ↓
- Stock or market?More than an industry move: ILMN rose 45.1% over the past 3 months, against 7.5% for the life sciences tools ETF IHI (iShares U.S. Medical Devices ETF). The S&P 500 rose 3.9%. Last month cut against the tape: ILMN rose 12.2% while the S&P 500 fell 0.6%.
- Past 1 to 3 yearsILMN has run far ahead of the market, rising 169% over the past year against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. The same gap shows up over 3 years (130% against 89.3%). A behind 62% of stocks worth at least $300 million over 10 years, but ahead of 77% of the stocks worth at least $300 million over 3 years. By year ↓
- Long termILMN turned $10,000 into $19,300 over the past decade, against $42,100 in the S&P 500. Growth of $10,000 ↓
- In a crashILMN fell harder than the S&P 500 in five of six sell-offs. The Covid crash was the exception: ILMN fell 31.0%, less than the S&P 500's 33.7%. On the flip side, in the 2022 bear market, ILMN fell 58.2%, against 24.5% for the S&P 500. That was more than TMO (Thermo Fisher Scientific, 19.8%) but less than NTRA (Natera, 68.0%). Crash tests ↓
- DiversificationAgainst the S&P 500, ILMN has a correlation of 0.47 over 5 years, more closely than 68% of stocks worth at least $300 million. Next to an index fund it is some diversification, but not a hedge. Market capture ↓
- Better options
- Nearby categories and themes
- LLY (Eli Lilly and Company, pharmaceuticals) and JNJ (Johnson & Johnson, pharmaceuticals) earned more than ILMN with less volatility over the past 5 years. LLY returned 40.7% a year at 32.8% volatility, against a loss of 7.8% a year at 46.9%.
- Whole market
- 2,406 of the 3,633 stocks and funds worth at least $500 million earned more than ILMN with less volatility over the past 5 years, among them AAPL (Apple), GOOG (Alphabet) and MSFT (Microsoft).
How much would $10,000 in ILMN have grown?
This chart tracks a hypothetical $10,000 investment in ILMN over the past 26 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of ILMN over the same span and ILMN's popular alternatives, among those that traded for the entire period. A second view covers the past 5 years, the period the better options further down the page are judged on. It shows not only where each investment ended up but also how smooth or uneven the path was.
- $10,000 invested in ILMN at the end of September 2000 would have grown to $124,118 by September 2026, more than the $84,332 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of ILMN, and GILD finished highest, at $636,955.
Choose a period
From the end of September 2000 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 490 of the 1,261 stocks and funds worth at least $500 million that traded the whole period ended ahead of ILMN; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- GILD$636,955+6,270% total · +17.3% a year
- DHR$450,317+4,403% total · +15.8% a year
- TMO$362,153+3,522% total · +14.8% a year
- BIO$335,462+3,255% total · +14.5% a year
- LLY$284,700+2,747% total · +13.7% a year
- ILMN$124,118+1,141% total · +10.2% a year
- SPY (S&P 500)$84,332+743% total · +8.5% a year
- A$59,185+492% total · +7.1% a year
- WAT$49,371+394% total · +6.3% a year
- RVTY$37,181+272% total · +5.2% a year
From the end of September 2021 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 3,037 of the 3,628 stocks and funds worth at least $500 million that traded the whole period ended ahead of ILMN; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- NTRA$37,089+271% total · +30.0% a year
- SPY (S&P 500)$19,000+90.0% total · +13.7% a year
- TWST$18,065+80.7% total · +12.6% a year
- WAT$12,298+23.0% total · +4.2% a year
- TMO$11,986+19.9% total · +3.7% a year
- A$11,334+13.3% total · +2.5% a year
- CDNA$10,257+2.6% total · +0.5% a year
- QGEN$9,482−5.2% total · −1.1% a year
- DHR$8,422−15.8% total · −3.4% a year
- ILMN$6,943−30.6% total · −7.0% a year
ILMN at a glance
This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout. These figures serve as the baseline for every comparison that follows.
- ILMN is still 47.5% below its all-time high.
- ILMN's deepest decline since it began trading in 2000 was 96.1%, from September 2000 to March 2003. It took about four years from the low to climb back to its old high.
- Over 25 full calendar years, ILMN's best was 2006, when it returned 179%, and its worst was 2002, when it lost 71.3%. It lost money in nine of those years.
The company
- Market value
- $40B
- Industry
- Medical - Diagnostics & Research
- Price history from
- July 2000
Returns
- Past 1 year
- +169%total return
- Past 3 years
- +130%+32.1% a year
- Past 5 years
- −33.3%−7.8% a year
- Past 10 years
- +93.0%+6.8% a year
- Best calendar year
- +179%2006
- Worst calendar year
- −71.3%2002
- Losing years
- 9 of 25full calendar years
Risk
- Volatility
- 46.9%typical yearly swing, 5 years
- Sharpe ratio
- 0.06return per unit of risk, 5 years
- Worst decline ever
- −96.1%Sep 2000 to Mar 2003
- From its all-time high
- −47.5%below the peak
ILMN against the whole market
Where ILMN ranks among every stock and fund, and what across the market has done better.
How does ILMN rank among all stocks?
This section ranks ILMN on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history. Where the comparisons with its popular alternatives show how ILMN stacks up against its peers, these rankings show where it stands in the market as a whole.
- ILMN's 1-year return ranks in the top 2% of the 3,287 stocks worth at least $300 million with 1 year of history.
- ILMN's worst decline of the past 10 years ranks in the bottom 17% of the 2,187 stocks worth at least $300 million, where the top fell the least.
Ranked against U.S.-listed stocks worth at least $300M that have enough history for each measure, so the count changes from row to row; smaller stocks are left out. Lower volatility and smaller declines rank higher.
| Measure | ILMN | Rank | Standing |
|---|---|---|---|
| 1-year return | +169% | 57 of 3,287 | top 2% |
| 3-year return | +130% | 703 of 3,017 | top 23% |
| 5-year return | −33.3% | 2,208 of 2,893 | bottom 25% |
| 10-year return | +93.0% | 1,370 of 2,202 | bottom 39% |
| Volatility, 5 years | 46.9% | 1,786 of 2,893 | bottom 39% |
| Sharpe ratio, 5 years | 0.06 | 2,218 of 2,893 | bottom 24% |
| Worst decline, past 10 years | −86.2% | 1,821 of 2,187 | bottom 18% |
What has beaten ILMN on both return and risk?
Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer). ILMN sits where the dashed lines cross. Anything in the green box above and to the left earned more than ILMN with smaller swings, a better trade-off over this period on both counts. Past results are no promise, but a name in the box is worth a closer look.
- 1,416 stocks and 990 ETFs worth at least $500 million sit in the green region: each earned more than ILMN over the past 5 years with smaller price swings. That is 66% of the 3,633 screened.
- Among those with at least half ILMN's swings, CAH has the best return for its risk: 42.1% a year at 24.7% volatility, 47% less than ILMN's 46.9%, and a Sharpe ratio (return above cash per unit of volatility) of 1.55 against 0.06 for ILMN. ATI earned the most, 61.8% a year, while still swinging less than ILMN (42.9% against 46.9%).
- Among ILMN's popular alternatives, WAT, TMO and A are in the region. WAT earned 4.5% a year against a loss of 7.8% a year for ILMN, at 33.9% volatility, 28% less than ILMN's 46.9%.
Annual return is the annualized total return with dividends reinvested, and volatility the annualized swing in daily prices, both over 5 years. Labeled dots are the strongest picks from the table below and the names called out above, colored by how close they sit to ILMN; faint dots are 89 more of the 2,406 in the green region (the strongest, one per fund family). 3,633 stocks and funds worth at least $500 million were screened. Hover over a dot for its figures.
- Popular alternatives
- Same and neighboring categories, and shared themes
- The whole market
- Others in the green region
- 1 with more than 1.6× ILMN's volatility is in the table only
Is there a better investment than ILMN?
Investments that beat ILMN over the past 5 years on return, volatility, drawdowns, consistency, crash losses or fees, from its popular alternatives out to the whole market.
- Among ILMN's popular alternatives, TMO, WAT and A earned more than ILMN with less volatility over the past 5 years. TMO returned 2.9% a year at 27.8% volatility, against a loss of 7.8% a year at 46.9%.
- Looking beyond its popular alternatives, LLY (pharmaceuticals) and JNJ (pharmaceuticals) earned more than ILMN with less volatility over the past 5 years. LLY returned 40.7% a year at 32.8% volatility, against a loss of 7.8% a year at 46.9%.
- Across the whole market, 2,406 of the 3,633 stocks and funds worth at least $500 million earned more than ILMN with less volatility over the past 5 years, among them AAPL, GOOG and MSFT.
How this works
The table below lists investments that beat ILMN over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes. It checks ILMN's popular alternatives first, then the rest of its own and neighboring categories, then every stock and fund worth at least $500 million, and shows the strongest few in each group. The full list of those with a higher return and lower volatility than ILMN follows the table.
Annual return is the annualized total return with dividends reinvested. Annual return, volatility and the Sharpe ratio cover 5 years; the worst decline covers the past 10 years. Green marks a better figure than ILMN's. "On the frontier" means no other option shown or tested earned more with less volatility. Funds that hold the same thing are shown once. Beyond the popular alternatives, nothing with more than 1.5× ILMN's volatility counts as better.
These figures cover the past 5 years. Green marks a better figure than ILMN's.
| Investment | Why it is better | Past 5 years | Downside | Long run | Fit | ||||
|---|---|---|---|---|---|---|---|---|---|
| Annual return?higher is better | Volatility?lower is calmer | Sharpe?return per unit of risk | Worst decline?past 10 years | 10Y returntotal | Corr. with ILMN?lower diversifies more | Expenseper year | |||
| −7.8% | 46.9% | 0.06 | −86.2% | +93.0% | 1.00 | — | |||
| +12.7% | 17.1% | 0.79 | −33.7% | +321% | 0.47 | 0.09% | |||
| Popular alternativesbest 6 shownThe investments people most often weigh against ILMN. 10 of 19 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +2.9% | 27.8% | 0.24 | −40.9% | +366% | 0.56 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +4.5% | 33.9% | 0.30 | −44.3% | +182% | 0.47 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +2.6% | 30.6% | 0.24 | −43.2% | +306% | 0.56 | — | ||
| Higher return, lower volatilitySmaller losses in recent crashes | −3.8% | 29.1% | 0.01 | −43.8% | +232% | 0.40 | — | ||
QGENQiagen N.V. · Life Sciences Tools | Higher return, lower volatilitySmaller losses in recent crashes | +0.6% | 26.9% | 0.15 | −41.4% | +111% | 0.46 | — | |
TWSTTwist Bioscience Corporation · Life Sciences Tools | Higher return in most periods | +3.9% | 78.3% | 0.44 | −94.5% | — | 0.37 | — | |
| Same and neighboring categories, and shared themesbest 6 shownEverything else in Life Sciences Tools and the categories next to it (Biotechnology, Medical Diagnostics, Contract Research, Pharmaceuticals), plus ILMN's specific themes. 53 of 87 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% | 0.04 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +12.7% | 17.9% | 0.76 | −27.4% | +196% | 0.15 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +17.1% | 20.7% | 0.87 | −26.8% | +226% | 0.09 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +22.8% | 24.9% | 0.95 | −30.5% | +200% | 0.21 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +16.3% | 24.8% | 0.74 | −43.4% | +241% | 0.20 | — | ||
ALNYAlnylam Pharmaceuticals, Inc. · Biotechnology | Higher return, similar volatilityHigher Sharpe, smaller worst decline | +2.5% | 50.9% | 0.29 | −58.2% | +514% | 0.06 | — | |
| The whole marketbest 8 shownEvery other stock and fund worth at least $500 million. 2,724 of 3,527 passed at least one test. | |||||||||
| On the frontierHigher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +51.2% | 33.4% | 1.41 | −79.7% | +1,387% | 0.18 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +12.5% | 28.2% | 0.56 | −37.1% | +946% | 0.26 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +31.5% | 38.5% | 0.91 | −56.6% | +1,505% | 0.29 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +14.5% | 23.0% | 0.71 | −35.1% | +553% | 0.46 | 0.18% | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +17.7% | 18.9% | 0.96 | −26.4% | +213% | 0.02 | 0.40% | ||
| Higher Sharpe, smaller worst declineHigher return in most periods | +55.2% | 54.4% | 1.08 | −59.6% | +3,701% | 0.23 | — | ||
| On the frontierHigher return, similar volatilityHigher Sharpe, smaller worst decline | +77.0% | 46.7% | 1.46 | −49.7% | +5,305% | 0.30 | — | ||
DGDollar General Corporation · Discount Retail | Similar return, lower volatilitySmaller losses in recent crashes | −7.4% | 37.0% | -0.01 | −72.6% | +127% | 0.05 | — | |
What these numbers mean for ILMN
- Annual return
- ILMN lost 7.8% a year over the past 5 years with dividends reinvested, against 12.7% a year for the S&P 500. At that pace, $10,000 became about $6,670. Annual return is the steady yearly rate that would produce the same total result, so investments held over the same span compare fairly. Guide: What is performance and return? →
- Volatility
- ILMN's volatility over the past 5 years was 46.9%, 2.7 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, ILMN's return lands within 46.9% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump. Guide: Understanding and measuring risk (volatility) →
- Sharpe ratio
- ILMN's Sharpe ratio over the past 5 years was 0.06, against 0.79 for the S&P 500, so ILMN earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings. Guide: Balancing reward with risk (Sharpe ratio) →
- Worst decline
- ILMN's worst fall from a peak to a low over the past 10 years was 86.2%, against 33.7% for the S&P 500. Losses and gains are not symmetric: climbing back from a 86.2% fall takes a 626% gain. Guide: Market crash risk and tail risk →
- Correlation
- Over the past 5 years, ILMN's monthly returns had a correlation of 0.47 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against ILMN instead: the lower it is, the more that option would diversify a ILMN holding. Guide: Correlation and diversification →
Show all 2,406 stocks and funds worth at least $500 million that earned more than ILMN with less volatility
Out of 3,633 tested over 5 years. The strongest 100 are listed, best first, with funds that hold the same thing listed once.
| # | Investment | Found in | Annual return | Volatility | Sharpe | Worst decline | 10Y return | Corr. with ILMN | Expense |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Whole market | +51.2% | 33.4% | 1.41 | −79.7% | +1,387% | 0.18 | — | |
| 2 | Whole market | +12.5% | 28.2% | 0.56 | −37.1% | +946% | 0.26 | — | |
| 3 | Whole market | +31.5% | 38.5% | 0.91 | −56.6% | +1,505% | 0.29 | — | |
| 4 | Whole market | +20.8% | 22.6% | 0.96 | −25.7% | +508% | 0.14 | — | |
| 5 | Whole market | +13.4% | 17.1% | 0.82 | −29.6% | +274% | 0.13 | — | |
| 6 | Whole market | +33.1% | 25.9% | 1.24 | −62.3% | +319% | -0.03 | — | |
| 7 | Whole market | +17.4% | 22.9% | 0.82 | −31.4% | +685% | 0.16 | — | |
| 8 | Whole market | +14.5% | 23.0% | 0.71 | −35.1% | +553% | 0.46 | 0.18% | |
| 9 | Whole market | +16.8% | 26.1% | 0.73 | −42.0% | +374% | 0.49 | — | |
| 10 | Whole market | +7.7% | 44.3% | 0.38 | −64.6% | +300% | 0.22 | — | |
| 11 | Whole market | +33.6% | 30.6% | 1.10 | −45.7% | +345% | 0.17 | — | |
| 12 | Whole market | +17.7% | 18.9% | 0.96 | −26.4% | +213% | 0.02 | 0.40% | |
| 13 | Whole market | +5.1% | 18.3% | 0.37 | −23.8% | +145% | 0.00 | — | |
| 14 | Whole market | +3.8% | 0.3% | 13.25 | −0.3% | — | 0.01 | 0.09% | |
| 15 | Whole market | +21.3% | 25.6% | 0.89 | −30.3% | +816% | -0.26 | — | |
| 16 | Whole market | +9.9% | 33.7% | 0.45 | −33.4% | +424% | 0.31 | — | |
| 17 | Whole market | +5.0% | 27.0% | 0.32 | −36.8% | +129% | 0.11 | — | |
| 18 | Whole market | +24.2% | 22.8% | 1.07 | −32.4% | +406% | 0.17 | — | |
| 19 | Whole market | +18.6% | 39.1% | 0.63 | −62.4% | +304% | 0.09 | — | |
| 20 | Whole market | +17.2% | 24.9% | 0.77 | −30.4% | +285% | 0.10 | — | |
| 21 | Whole market | +6.4% | 26.1% | 0.37 | −44.0% | +253% | -0.11 | — | |
| 22 | Whole market | +17.3% | 18.2% | 0.97 | −40.0% | +352% | 0.29 | — | |
| 23 | Whole market | +51.8% | 37.5% | 1.31 | −71.7% | +768% | 0.03 | — | |
| 24 | Same or nearby category | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% | 0.04 | — | |
| 25 | Whole market | +27.5% | 36.9% | 0.85 | −46.7% | +510% | 0.02 | — | |
| 26 | Whole market | +9.3% | 19.2% | 0.56 | −30.1% | +344% | -0.04 | — | |
| 27 | ESLTElbit Systems Ltd. · Aerospace & Defense | Whole market | +39.8% | 34.6% | 1.15 | −35.4% | +765% | 0.07 | — |
| 28 | Whole market | +2.9% | 29.2% | 0.24 | −50.6% | +309% | 0.18 | — | |
| 29 | Whole market | +18.9% | 37.3% | 0.65 | −53.9% | +194% | 0.09 | — | |
| 30 | Whole market | +15.8% | 24.6% | 0.72 | −30.7% | +576% | 0.23 | — | |
| 31 | JAAAJanus Henderson AAA CLO ETF · CLO Bonds | Whole market | +5.1% | 1.7% | 2.98 | −2.6% | — | 0.18 | 0.20% |
| 32 | Whole market | +6.6% | 27.8% | 0.37 | −41.8% | +226% | 0.16 | — | |
| 33 | Whole market | +47.3% | 32.5% | 1.36 | −68.9% | +1,028% | 0.14 | — | |
| 34 | Whole market | +42.1% | 24.7% | 1.55 | −46.1% | +349% | 0.18 | — | |
| 35 | Whole market | +6.6% | 41.9% | 0.36 | −57.4% | +184% | -0.12 | — | |
| 36 | Whole market | +4.0% | 20.2% | 0.29 | −29.8% | +93.4% | 0.04 | — | |
| 37 | Whole market | +8.4% | 15.3% | 0.60 | −28.4% | +202% | 0.36 | 0.08% | |
| 38 | Whole market | +18.5% | 28.0% | 0.75 | −38.5% | +1,168% | 0.38 | — | |
| 39 | Whole market | +6.3% | 29.4% | 0.35 | −48.5% | +154% | 0.10 | — | |
| 40 | Whole market | +12.5% | 31.3% | 0.53 | −37.1% | +303% | 0.03 | — | |
| 41 | CHTChunghwa Telecom Co., Ltd. · Integrated Telecommunications | Whole market | +7.7% | 13.3% | 0.63 | −23.8% | +101% | 0.10 | — |
| 42 | Whole market | +19.0% | 32.0% | 0.71 | −44.6% | +752% | 0.35 | — | |
| 43 | BCHBanco de Chile · Banks | Whole market | +25.2% | 28.2% | 0.94 | −58.4% | +180% | 0.07 | — |
| 44 | Whole market | +6.5% | 20.9% | 0.41 | −34.4% | +156% | 0.04 | — | |
| 45 | Whole market | +12.3% | 27.3% | 0.56 | −43.8% | +151% | 0.13 | — | |
| 46 | Same or nearby category | +12.7% | 17.9% | 0.76 | −27.4% | +196% | 0.15 | — | |
| 47 | Whole market | +23.5% | 18.8% | 1.22 | −75.2% | +350% | 0.14 | — | |
| 48 | Whole market | +3.2% | 24.1% | 0.25 | −37.9% | +107% | 0.32 | — | |
| 49 | Whole market | +6.1% | 20.0% | 0.40 | −31.6% | +270% | 0.12 | — | |
| 50 | Same or nearby category | +17.1% | 20.7% | 0.87 | −26.8% | +226% | 0.09 | — | |
| 51 | Whole market | +48.3% | 44.5% | 1.11 | −48.3% | +2,380% | 0.29 | — | |
| 52 | Same or nearby category | +22.8% | 24.9% | 0.95 | −30.5% | +200% | 0.21 | — | |
| 53 | AEEAmeren Corporation · Electric Utilities | Whole market | +7.9% | 19.4% | 0.49 | −29.1% | +192% | 0.00 | — |
| 54 | EXPDExpeditors International of Washington, Inc. · Freight & Logistics | Whole market | +12.0% | 27.1% | 0.56 | −35.6% | +349% | 0.27 | — |
| 55 | Same or nearby category | +16.3% | 24.8% | 0.74 | −43.4% | +241% | 0.20 | — | |
| 56 | Same or nearby category | +19.6% | 24.9% | 0.85 | −24.9% | +266% | 0.17 | — | |
| 57 | EWJiShares MSCI Japan ETF · International Equity | Whole market | +9.2% | 18.8% | 0.57 | −33.1% | +132% | 0.38 | 0.49% |
| 58 | VRSNVeriSign, Inc. · Internet Services | Whole market | +7.8% | 25.9% | 0.42 | −38.9% | +308% | 0.11 | — |
| 59 | Whole market | +11.5% | 17.5% | 0.71 | −35.0% | +302% | 0.49 | 0.03% | |
| 60 | CHDChurch & Dwight Co., Inc. · Household & Personal Products | Whole market | +6.1% | 21.1% | 0.39 | −31.7% | +154% | -0.03 | — |
| 61 | Whole market | +12.8% | 16.9% | 0.80 | −34.0% | +324% | 0.47 | 0.03% | |
| 62 | MUSAMurphy USA Inc. · Convenience Stores | Whole market | +26.1% | 31.2% | 0.90 | −35.5% | +706% | -0.06 | — |
| 63 | Whole market | +9.0% | 36.6% | 0.42 | −56.1% | +548% | 0.35 | — | |
| 64 | CMSCMS Energy Corporation · Electric Utilities | Whole market | +5.6% | 19.0% | 0.38 | −29.6% | +123% | -0.05 | — |
| 65 | XLPState Street Consumer Staples Select Sector SPDR ETF · Consumer Staples | Whole market | +7.2% | 13.8% | 0.57 | −24.5% | +121% | 0.17 | 0.08% |
| 66 | VPLVanguard FTSE Pacific ETF · International Equity | Whole market | +9.5% | 18.6% | 0.58 | −33.9% | +141% | 0.38 | 0.07% |
| 67 | CHRWC.H. Robinson Worldwide, Inc. · Freight & Logistics | Whole market | +9.9% | 34.4% | 0.45 | −40.6% | +157% | 0.24 | — |
| 68 | FCFSFirstCash Holdings, Inc · Consumer Finance | Whole market | +20.6% | 30.5% | 0.77 | −50.2% | +422% | 0.12 | — |
| 69 | NEUNewMarket Corporation · Specialty Chemicals | Whole market | +21.0% | 26.8% | 0.85 | −40.7% | +165% | 0.11 | — |
| 70 | Same or nearby category | +8.7% | 35.7% | 0.41 | −28.7% | +257% | 0.15 | — | |
| 71 | Whole market | +27.1% | 26.5% | 1.04 | −61.0% | +214% | 0.11 | — | |
| 72 | PDBCInvesco Optimum Yield Diversified Commodity Strategy No K-1 ETF · Broad Commodities | Whole market | +11.7% | 19.3% | 0.67 | −40.7% | +153% | 0.07 | 0.74% |
| 73 | QYLDGlobal X - Nasdaq 100 Covered Call ETF · Equity Income | Whole market | +8.4% | 15.0% | 0.62 | −24.7% | +156% | 0.52 | 0.60% |
| 74 | Whole market | +17.3% | 24.3% | 0.78 | −43.6% | +537% | 0.27 | — | |
| 75 | Same or nearby category | +9.5% | 24.5% | 0.49 | −37.6% | +95.1% | 0.02 | — | |
| 76 | SFMSprouts Farmers Market, Inc. · Grocery Stores | Whole market | +23.8% | 40.3% | 0.74 | −65.2% | +202% | 0.02 | — |
| 77 | ERIEErie Indemnity Company · Property & Casualty Insurance | Whole market | +6.3% | 31.4% | 0.35 | −60.9% | +200% | 0.05 | — |
| 78 | NYTThe New York Times Company · Media | Whole market | +6.2% | 30.6% | 0.35 | −49.9% | +559% | 0.19 | — |
| 79 | GENGen Digital Inc. · Cybersecurity | Whole market | +0.4% | 32.9% | 0.18 | −48.4% | +107% | 0.14 | — |
| 80 | NFGNational Fuel Gas Company · Oil & Gas | Whole market | +9.8% | 22.1% | 0.53 | −44.3% | +113% | -0.04 | — |
| 81 | VIRTVirtu Financial, Inc. · Capital Markets | Whole market | +20.8% | 33.8% | 0.73 | −56.2% | +545% | 0.25 | — |
| 82 | USLMUnited States Lime & Minerals, Inc. · Construction Materials | Whole market | +35.6% | 36.1% | 1.03 | −45.9% | +803% | 0.14 | — |
| 83 | Whole market | +12.8% | 22.9% | 0.64 | −36.4% | +429% | 0.20 | — | |
| 84 | Whole market | +36.0% | 31.0% | 1.15 | −80.9% | +139% | 0.28 | — | |
| 85 | FTGCFirst Trust Global Tactical Commodity Strategy Fund · Alternatives | Whole market | +12.9% | 15.6% | 0.86 | −35.9% | +139% | 0.10 | 0.98% |
| 86 | DXJWisdomTree Japan Hedged Equity Fund · International Equity | Whole market | +26.6% | 19.1% | 1.34 | −39.1% | +428% | 0.20 | 0.48% |
| 87 | LVHIFranklin International Low Volatility High Dividend Index ETF · International Equity | Whole market | +17.0% | 11.1% | 1.48 | −32.4% | +194% | 0.20 | 0.40% |
| 88 | FTLSFirst Trust Long/Short Equity ETF · Broad Market | Whole market | +10.2% | 10.4% | 0.99 | −20.6% | +158% | 0.40 | 0.95% |
| 89 | CSWCSW Industrials, Inc. · Industrial Products | Whole market | +17.1% | 34.4% | 0.63 | −46.2% | +867% | 0.29 | — |
| 90 | PTLCPacer Trendpilot US Large Cap ETF · Broad Market | Whole market | +9.5% | 11.8% | 0.83 | −26.6% | +188% | 0.36 | 0.60% |
| 91 | Whole market | +14.7% | 16.8% | 0.91 | −37.0% | +204% | 0.10 | — | |
| 92 | BALTInnovator Defined Wealth Shield ETF · Crypto | Whole market | +6.3% | 3.3% | 1.85 | −4.9% | — | 0.33 | 0.69% |
| 93 | Whole market | +19.5% | 25.2% | 0.84 | −55.8% | +238% | 0.21 | — | |
| 94 | Whole market | +31.1% | 31.9% | 1.01 | −43.4% | +936% | 0.44 | — | |
| 95 | BAHBooz Allen Hamilton Holding Corporation · Business Services | Whole market | +0.4% | 32.6% | 0.18 | −66.6% | +197% | 0.10 | — |
| 96 | RLIRLI Corp. · Property & Casualty Insurance | Whole market | +8.1% | 23.9% | 0.45 | −43.5% | +206% | -0.04 | — |
| 97 | Whole market | +17.4% | 43.4% | 0.59 | −56.9% | +1,628% | 0.34 | — | |
| 98 | NICNicolet Bankshares, Inc. · Banks - Regional | Whole market | +19.0% | 30.1% | 0.73 | −44.3% | +344% | 0.19 | — |
| 99 | AORiShares Core 60/40 Balanced Allocation ETF · Multi-Asset | Whole market | +6.4% | 10.7% | 0.64 | −23.0% | +118% | 0.41 | 0.20% |
| 100 | Whole market | +33.2% | 29.4% | 1.13 | −54.9% | +483% | 0.09 | — |
ILMN against its popular alternatives
The investments people most often weigh against ILMN, compared period by period and year by year.
How do ILMN's risk and return compare with its alternatives?
This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings. Investments toward the upper left earned more for a smoother ride, and those toward the lower right earned less for a rougher one. The dashed lines cross at ILMN, which divides the map into what did better or worse on each measure.
- Seven of the 19 popular alternatives, led by WAT, TMO and A, were both more rewarding and calmer than ILMN over the past 5 years, earning a higher annual return with lower volatility.
- Over the past 5 years, ILMN returned -7.8% a year, less than the S&P 500's 12.7%, with higher volatility (46.9% against 17.1%).
Green points earned more than ILMN with less volatility; red points earned less with more. Hover over a point for its figures. Total returns with dividends reinvested, annualized.
All figures
| Investment | Annual return | Volatility |
|---|---|---|
| NTRA Natera, Inc. | +29.3% | 57.6% |
| SPY S&P 500State Street SPDR S&P 500 ETF | +12.7% | 17.1% |
| GH Guardant Health, Inc. | +8.8% | 67.9% |
| WAT Waters Corporation | +4.5% | 33.9% |
| TWST Twist Bioscience Corporation | +3.9% | 78.3% |
| TMO Thermo Fisher Scientific Inc. | +2.9% | 27.8% |
| A Agilent Technologies, Inc. | +2.6% | 30.6% |
| QGEN Qiagen N.V. | +0.6% | 26.9% |
| CDNA CareDx, Inc | −0.8% | 79.5% |
| RVTY Revvity, Inc. | −2.2% | 35.1% |
| DHR Danaher Corporation | −3.8% | 29.1% |
| BRKR Bruker Corporation | −6.3% | 44.3% |
| ILMN This pageIllumina, Inc. | −7.8% | 46.9% |
| TECH Bio-Techne Corporation | −10.2% | 39.4% |
| CRSP CRISPR Therapeutics AG | −12.7% | 60.9% |
| BIO Bio-Rad Laboratories, Inc. | −13.9% | 37.9% |
| TXG 10x Genomics, Inc. | −15.1% | 70.8% |
| AVTR Avantor, Inc. | −15.5% | 41.0% |
| SOPH SOPHiA GENETICS S.A. | −17.1% | 81.6% |
| NTLA Intellia Therapeutics, Inc. | −38.0% | 78.0% |
| PACB Pacific Biosciences of California, Inc. | −40.0% | 97.0% |
Has ILMN consistently beaten its popular alternatives?
This section compares ILMN with the investments people most often weigh against it, checking each one over eight periods from one month to ten years. Counting how often an alternative earned more than ILMN helps separate lasting outperformance from a single strong stretch.
- CDNA outperformed ILMN in every long-term period and in all but one short-term period, the most consistent record in the group.
- Two of the 21 popular alternatives, CDNA and TWST, outperformed ILMN in at least 3 of 5 short-term and 2 of 3 long-term timeframes.
- NTRA, WAT and TMO earned more for the risk they took than ILMN (a higher Sharpe ratio) and fell less in their worst decline of the past 10 years.
A green cell means the alternative earned more than ILMN over that period. "Qualified" marks those that did so in at least 3 of 5 short-term periods and 2 of 3 long-term periods.
| Investment | Periods outperformed | Short term | Long term | Risk · 5 years | Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Volatilitylower is calmer | Sharpehigher is better | Worst declinepast 10 years | Expense | Assets | Overlapsame sectors | ||
| ILMN Illumina, Inc. (this page) | — | +12.2% | +45.1% | +102% | +99.4% | +169% | +130% | −33.3% | +93.0% | 46.9% | 0.06 | −86.2% | — | $40B | — |
| CDNA QualifiedCareDx, Inc | 5/5 short3/3 longAll-weather | +27.4% | +80.3% | +225% | +262% | +355% | +1,203% | −3.8% | +1,634% | 79.5% | 0.39 | −94.9% | — | $3.6B | — |
| TWST QualifiedTwist Bioscience Corporation | 4/5 short2/3 long | −13.9% | +63.2% | +131% | +341% | +336% | +752% | +21.2% | — | 78.3% | 0.44 | −94.5% | — | $9.4B | — |
| NTRA Medical - Diagnostics & ResearchNatera, Inc. | 1/5 short3/3 long | +9.5% | +54.6% | +95.4% | +77.4% | +115% | +896% | +261% | +3,841% | 57.6% | 0.74 | −77.7% | — | $59B | — |
| RVTY Medical - Diagnostics & ResearchRevvity, Inc. | 1/5 short2/3 long | +8.6% | +46.6% | +67.8% | +59.3% | +64.0% | +54.6% | −10.6% | +203% | 35.1% | 0.11 | −59.0% | — | $17B | — |
| TMO Medical - Diagnostics & ResearchThermo Fisher Scientific Inc. | 0/5 short2/3 long | +4.3% | +30.7% | +30.9% | +16.3% | +26.8% | +49.5% | +15.1% | +366% | 27.8% | 0.24 | −40.9% | — | $254B | — |
| A Medical - Diagnostics & ResearchAgilent Technologies, Inc. | 0/5 short2/3 long | +7.1% | +33.1% | +43.6% | +26.4% | +22.0% | +62.1% | +13.8% | +306% | 30.6% | 0.24 | −43.2% | — | $49B | — |
| DHR Medical - Diagnostics & ResearchDanaher Corporation | 0/5 short2/3 long | +4.0% | +11.6% | +15.0% | −2.2% | +8.3% | +10.8% | −17.6% | +232% | 29.1% | 0.01 | −43.8% | — | $157B | — |
| WAT Medical - Diagnostics & ResearchWaters Corporation | 0/5 short2/3 long | +4.5% | +23.9% | +31.9% | +15.9% | +29.0% | +74.6% | +24.4% | +182% | 33.9% | 0.30 | −44.3% | — | $43B | — |
| BRKR Medical - DevicesBruker Corporation | 0/5 short2/3 long | −9.2% | −0.3% | +36.3% | +16.6% | +47.4% | −5.0% | −27.7% | +171% | 44.3% | 0.08 | −68.7% | — | $8.5B | — |
| QGEN Medical - Diagnostics & ResearchQiagen N.V. | 0/5 short2/3 long | +9.2% | +20.8% | +20.2% | +8.7% | +6.3% | +45.9% | +3.0% | +111% | 26.9% | 0.15 | −41.4% | — | $10B | — |
| GH Medical - Diagnostics & ResearchGuardant Health, Inc. | 0/5 short2/3 long | −6.5% | +9.8% | +78.5% | +59.8% | +132% | +534% | +52.8% | — | 67.9% | 0.46 | −91.0% | — | $22B | — |
| CRSP BiotechnologyCRISPR Therapeutics AG | 0/5 short1/3 long | −14.5% | +6.2% | −13.5% | −7.2% | −32.6% | +29.2% | −49.3% | +258% | 60.9% | 0.08 | −85.1% | — | $4.8B | — |
| TECH BiotechnologyBio-Techne Corporation | 0/5 short1/3 long | +0.2% | +1.4% | +20.2% | +22.2% | +16.7% | +15.1% | −41.4% | +191% | 39.4% | -0.08 | −67.2% | — | $11B | — |
| BIO Medical - DevicesBio-Rad Laboratories, Inc. | 0/5 short1/3 long | −6.0% | +17.4% | +16.9% | +16.1% | +10.1% | +14.1% | −52.5% | +115% | 37.9% | -0.21 | −73.8% | — | $9.5B | — |
| TXG Biotechnology10x Genomics, Inc. | 4/5 short0/3 long | −9.7% | +65.3% | +191% | +330% | +444% | +81.2% | −55.8% | — | 70.8% | 0.12 | −96.5% | — | $9.3B | — |
| GRAL Medical - Diagnostics & ResearchGRAIL Inc. | 3/5 short0/3 long | +15.5% | +80.9% | +143% | +40.3% | +35.7% | — | — | — | — | — | −62.9% | — | $5.6B | — |
| PACB Medical - DevicesPacific Biosciences of California, Inc. | 1/5 short0/3 long | +44.1% | +44.1% | +12.6% | +6.5% | −1.0% | −73.5% | −92.2% | −77.9% | 97.0% | -0.04 | −98.2% | — | $609M | — |
| AVTR Medical - Instruments & SuppliesAvantor, Inc. | 1/5 short0/3 long | +10.1% | +55.9% | +95.5% | +45.0% | +9.5% | −19.1% | −56.9% | — | 41.0% | -0.20 | −83.2% | — | $11B | — |
| NTLA BiotechnologyIntellia Therapeutics, Inc. | 0/5 short0/3 long | −3.1% | +8.4% | −22.2% | +28.6% | −57.7% | −55.6% | −90.8% | −5.0% | 78.0% | -0.22 | −96.5% | — | $1.7B | — |
| SOPH Medical - Healthcare Information ServicesSOPHiA GENETICS S.A. | 0/5 short0/3 long | −15.9% | +9.5% | +33.5% | +48.4% | +65.4% | +128% | −60.9% | — | 81.6% | 0.17 | −91.3% | — | $590M | — |
| TEM Medical - Healthcare Information ServicesTempus AI, Inc. | 0/5 short0/3 long | −14.5% | +37.9% | +17.6% | +7.0% | −27.8% | — | — | — | — | — | −59.8% | — | $12B | — |
How did ILMN do year by year?
This table shows each investment's total return in every full calendar year since 2001, along with where ILMN ranked among its popular alternatives each year. Annual results reveal how consistently each one kept pace with ILMN and how far its good and bad years diverged, detail that multiyear averages tend to smooth over.
- ILMN finished ahead of the S&P 500 in 13 of its 25 full calendar years, and behind it in each of the last seven.
- Ranked against its popular alternatives each year, ILMN finished in the top quarter in 12 of 25 years and in the bottom quarter in five. In 2025, it ranked 14 of 22.
- Among its popular alternatives, GH came out ahead of ILMN most often, in five of the seven years both traded.
Newest year first. Green marks a year in which the fund came out ahead of ILMN; gray means the two finished within a fraction of a point. The rank row places ILMN among the alternatives that traded the full year; dark green is the top quarter and red the bottom quarter.
| Investment | Years ahead of ILMN | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ILMN This pageIllumina, Inc. | — | −1.8% | −1.3% | −31.1% | −46.9% | +2.8% | +11.5% | +10.6% | +37.3% | +70.7% | −33.3% | +4.0% | +66.9% | +99.0% | +82.4% | −51.9% | +106% | +17.8% | −12.1% | +50.8% | +179% | +48.6% | +34.4% | +109% | −71.3% | −26.9% |
| Rank among alternatives | Top quarter in 12 of 25 | 14 of 22 | 10 of 20 | 20 of 20 | 11 of 20 | 13 of 19 | 17 of 19 | 12 of 17 | 4 of 15 | 2 of 15 | 11 of 13 | 9 of 12 | 1 of 11 | 2 of 11 | 1 of 11 | 10 of 11 | 1 of 10 | 9 of 10 | 2 of 10 | 3 of 10 | 1 of 10 | 1 of 10 | 2 of 10 | 3 of 10 | 8 of 10 | 5 of 10 |
| SPY S&P 500State Street SPDR S&P 500 ETF | 12 of 25 | +17.7% | +24.9% | +26.2% | −18.2% | +28.7% | +18.3% | +31.2% | −4.6% | +21.7% | +12.0% | +1.2% | +13.5% | +32.3% | +16.0% | +1.9% | +15.1% | +26.4% | −36.8% | +5.1% | +15.9% | +4.8% | +10.7% | +28.2% | −21.6% | −11.7% |
| CDNA CareDx, Inc | 5 of 11 | −12.0% | +78.4% | +5.2% | −74.9% | −37.2% | +236% | −14.2% | +243% | +172% | −57.8% | −11.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| TWST Twist Bioscience Corporation | 3 of 7 | −31.7% | +26.1% | +54.8% | −69.2% | −45.2% | +573% | −9.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| NTRA Natera, Inc. | 7 of 10 | +44.7% | +153% | +55.9% | −57.0% | −6.2% | +195% | +141% | +55.3% | −23.2% | +8.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| RVTY Revvity, Inc. | 10 of 25 | −13.1% | +2.4% | −21.9% | −30.1% | +40.4% | +48.2% | +24.0% | +7.8% | +40.8% | −2.1% | +23.2% | +6.8% | +31.0% | +60.4% | −21.6% | +27.1% | +50.6% | −45.9% | +18.4% | −4.5% | +6.2% | +33.9% | +112% | −75.7% | −32.7% |
| TMO Thermo Fisher Scientific Inc. | 12 of 25 | +11.8% | −1.7% | −3.4% | −17.3% | +43.5% | +43.7% | +45.6% | +18.2% | +35.0% | −0.1% | +13.8% | +13.1% | +75.8% | +43.2% | −18.8% | +16.1% | +40.0% | −40.9% | +27.4% | +50.3% | −0.2% | +19.8% | +25.3% | −15.7% | +5.6% |
| A Agilent Technologies, Inc. | 10 of 25 | +1.9% | −2.7% | −6.4% | −5.5% | +35.5% | +39.8% | +27.5% | +1.7% | +48.3% | +10.2% | +3.5% | +0.8% | +41.1% | +18.4% | −15.7% | +33.4% | +98.7% | −57.4% | +5.4% | +11.1% | +38.1% | −17.6% | +62.8% | −37.0% | −47.9% |
| DHR Danaher Corporation | 13 of 25 | +0.4% | −0.4% | −1.2% | −19.0% | +48.6% | +45.4% | +49.5% | +11.8% | +20.0% | +73.2% | +9.3% | +11.6% | +38.3% | +19.1% | −0.1% | +25.7% | +33.0% | −35.4% | +21.3% | +30.1% | −2.7% | +25.3% | +39.7% | +9.1% | −11.7% |
| WAT Waters Corporation | 13 of 25 | +2.4% | +12.7% | −3.9% | −8.1% | +50.6% | +5.9% | +23.9% | −2.4% | +43.8% | −0.1% | +19.4% | +12.7% | +14.8% | +17.6% | −4.7% | +25.4% | +69.1% | −53.6% | +61.5% | +29.5% | −19.2% | +41.1% | +52.3% | −43.8% | −53.6% |
| BRKR Bruker Corporation | 9 of 25 | −19.3% | −20.0% | +7.8% | −18.3% | +55.3% | +6.6% | +71.8% | −12.8% | +62.7% | −12.2% | +23.7% | −0.8% | +29.8% | +22.7% | −25.2% | +37.7% | +199% | −69.7% | +77.1% | +54.5% | +20.7% | −11.5% | −6.4% | −70.3% | −30.6% |
| QGEN Qiagen N.V. | 11 of 25 | +12.5% | +2.6% | −12.9% | −10.3% | +5.2% | +56.4% | −1.9% | +11.4% | +10.7% | +1.3% | +17.8% | −1.5% | +31.2% | +31.4% | −29.3% | −12.4% | +27.1% | −16.5% | +39.1% | +28.8% | +7.3% | −8.5% | +131% | −72.1% | −46.3% |
| GH Guardant Health, Inc. | 5 of 7 | +234% | +12.9% | −0.5% | −72.8% | −22.4% | +64.9% | +108% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CRSP CRISPR Therapeutics AG | 4 of 9 | +33.2% | −37.1% | +54.0% | −46.4% | −50.5% | +151% | +113% | +21.7% | +15.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| TECH Bio-Techne Corporation | 10 of 25 | −17.9% | −6.3% | −6.5% | −35.7% | +63.4% | +45.4% | +52.7% | +12.6% | +27.5% | +15.8% | −1.3% | −1.1% | +40.9% | +1.9% | +5.5% | −2.5% | +8.0% | −1.9% | +19.2% | −1.2% | +44.3% | +2.8% | +32.5% | −22.4% | +2.0% |
| BIO Bio-Rad Laboratories, Inc. | 12 of 25 | −7.8% | +1.7% | −23.2% | −44.4% | +29.6% | +57.5% | +59.4% | −2.7% | +30.9% | +31.5% | +15.0% | −2.5% | +17.7% | +9.4% | −7.5% | +7.7% | +28.1% | −27.3% | +25.6% | +26.1% | +14.1% | −0.5% | +49.0% | +22.3% | +99.1% |
| TXG 10x Genomics, Inc. | 4 of 6 | +13.6% | −74.3% | +53.6% | −75.5% | +5.2% | +85.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| GRAL GRAIL Inc. | 1 of 1 | +379% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| PACB Pacific Biosciences of California, Inc. | 6 of 15 | +2.2% | −81.3% | +19.9% | −60.0% | −21.1% | +405% | −30.5% | +180% | −30.5% | −71.1% | +67.5% | +49.9% | +208% | −39.3% | −82.4% | — | — | — | — | — | — | — | — | — | — |
| AVTR Avantor, Inc. | 3 of 6 | −45.6% | −7.7% | +8.3% | −50.0% | +49.7% | +55.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| NTLA Intellia Therapeutics, Inc. | 3 of 9 | −22.9% | −61.8% | −12.6% | −70.5% | +117% | +271% | +7.5% | −29.0% | +46.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| SOPH SOPHiA GENETICS S.A. | 2 of 4 | +52.1% | −34.8% | +129% | −85.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| TEM Tempus AI, Inc. | 1 of 1 | +74.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Risk and diversification
How ILMN has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.
What were ILMN's worst declines?
A drawdown is the decline from a peak to the lowest point before a new high. This section presents ILMN's five deepest drawdowns since it began trading in 2000, alongside the S&P 500's return over the same dates, and how long each took to recover. Together, these figures show how much an investor could have lost and how long it took to get back to even.
- In all five of ILMN's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: ILMN fell 86.2% from August 2021 to April 2025, while the S&P 500 rose 17.2%.
- The slowest recovery came after ILMN fell 96.1% from September 2000 to March 2003; it did not regain that peak until July 2007, four years later.
Green means ILMN fell less than the S&P 500 over the same dates. Based on daily closing prices with dividends reinvested.
| During | ILMN fell | S&P 500, same dates | Peak | Low | Time to the low | Back at the peak | Time to recover |
|---|---|---|---|---|---|---|---|
| Dot-com bust | −96.1% | −43.1% | Sep 2000 | Mar 2003 | 2.5 years | Jul 2007 | 4.3 years |
| 2022 bear market | −86.2% | +17.2% | Aug 2021 | Apr 2025 | 3.7 years | Not yet | — |
| 2011 euro debt crisis | −66.7% | −7.7% | Jul 2011 | Dec 2011 | 5 months | Jul 2013 | 19 months |
| 2008 financial crisis | −57.9% | −38.6% | Aug 2008 | Nov 2008 | 3 months | Aug 2010 | 21 months |
| 2015 China and oil sell-off | −49.2% | +8.5% | Jul 2015 | Dec 2016 | 17 months | Jan 2018 | 13 months |
How did ILMN do in stock market crashes?
This section measures how far ILMN, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000. A smaller decline means an investment held up better, and comparing results across crashes shows whether that resilience was consistent or a one-off.
Note: ILMN began trading on July 28, 2000, so its row reads "Not yet trading" for the dot-com bust. The older alternatives and the S&P 500 show how those crashes played out.
- ILMN fell further than the S&P 500 in six of the nine crashes it has traded through. The clearest case was the 2022 bear market, when ILMN fell 58.2% and the S&P 500 fell 24.5%.
- Among its popular alternatives, DHR held up best, falling less than ILMN in eight of the nine crashes they both traded through.
- ILMN began trading after the dot-com bust, but eight of its popular alternatives lived through it. The mildest fall among them was BIO's 29.1%, against 47.5% for the S&P 500.
Newest crash first. Each figure is the fund's deepest fall within the crash window; green means a smaller fall than ILMN.
| Investment | Held up better | 2023 regional bank crisisMar 2023 | 2022 bear marketJan 2022 | Covid crashFeb 2020 | Late-2018 sell-offSep 2018 | February 2018 volatility shockFeb 2018 | 2015 China and oil sell-offAug 2015 | 2011 euro debt crisisJul 2011 | 2010 flash crashMay 2010 | 2008 financial crisisOct 2007 | Dot-com bustMar 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ILMN This pageIllumina, Inc. | — | −6.7% | −58.2% | −31.0% | −25.8% | −5.3% | −36.1% | −48.7% | −1.9% | −57.9% | Not yet trading |
| SPY S&P 500State Street SPDR S&P 500 ETF | 6 of 9 | −3.4% | −24.5% | −33.7% | −19.3% | −6.5% | −12.8% | −17.9% | −1.5% | −55.2% | −47.5% |
| CDNA CareDx, Inc | 1 of 6 | −10.8% | −65.3% | −50.6% | −33.7% | −2.9% | −42.7% | — | — | — | — |
| TWST Twist Bioscience Corporation | 0 of 3 | −12.7% | −66.0% | −43.9% | — | — | — | — | — | — | — |
| NTRA Natera, Inc. | 1 of 6 | −6.2% | −68.0% | −57.0% | −51.1% | −11.2% | −61.5% | — | — | — | — |
| RVTY Revvity, Inc. | 5 of 9 | −3.2% | −38.1% | −29.3% | −26.1% | −7.7% | −23.6% | −31.2% | −3.4% | −62.6% | −91.6% |
| TMO Thermo Fisher Scientific Inc. | 7 of 9 | −2.4% | −19.8% | −24.8% | −17.2% | −8.7% | −14.7% | −24.4% | −3.6% | −53.9% | −41.8% |
| A Agilent Technologies, Inc. | 6 of 9 | −3.7% | −25.3% | −25.8% | −16.1% | −8.7% | −17.6% | −37.3% | −4.2% | −67.6% | −92.4% |
| DHR Danaher Corporation | 8 of 9 | −3.2% | −22.8% | −25.9% | −13.4% | −9.8% | −14.0% | −21.8% | −0.6% | −45.7% | −33.7% |
| WAT Waters Corporation | 6 of 9 | −1.6% | −26.3% | −25.3% | −14.7% | −9.7% | −16.6% | −26.4% | −3.4% | −60.7% | −80.1% |
| BRKR Bruker Corporation | 5 of 9 | −2.5% | −38.0% | −36.2% | −24.1% | −13.4% | −19.9% | −39.0% | −5.5% | −80.2% | — |
| QGEN Qiagen N.V. | 7 of 9 | −0.4% | −21.3% | −12.4% | −14.0% | −7.0% | −27.8% | −25.9% | −2.6% | −45.1% | −92.1% |
| GH Guardant Health, Inc. | 0 of 3 | −13.4% | −70.6% | −33.5% | — | — | — | — | — | — | — |
| CRSP CRISPR Therapeutics AG | 1 of 5 | −9.8% | −41.0% | −42.0% | −51.1% | −16.3% | — | — | — | — | — |
| TECH Bio-Techne Corporation | 8 of 9 | −3.6% | −39.6% | −23.5% | −34.8% | −4.5% | −24.9% | −18.8% | −0.4% | −43.8% | −69.6% |
| BIO Bio-Rad Laboratories, Inc. | 7 of 9 | −1.9% | −45.3% | −21.8% | −29.7% | −8.0% | −18.1% | −25.4% | −0.5% | −50.9% | −29.1% |
| TXG 10x Genomics, Inc. | 0 of 3 | −8.1% | −81.1% | −43.1% | — | — | — | — | — | — | — |
| PACB Pacific Biosciences of California, Inc. | 1 of 7 | −6.7% | −79.3% | −47.4% | −28.1% | −10.0% | −34.7% | −75.2% | — | — | — |
| AVTR Avantor, Inc. | 2 of 3 | −6.2% | −50.5% | −53.9% | — | — | — | — | — | — | — |
| NTLA Intellia Therapeutics, Inc. | 0 of 5 | −11.0% | −66.1% | −38.3% | −60.4% | −9.6% | — | — | — | — | — |
| SOPH SOPHiA GENETICS S.A. | 1 of 2 | 0.0% | −84.4% | — | — | — | — | — | — | — | — |
How closely does ILMN move with the S&P 500?
Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell. An investment that captures more of the gains than the losses has compounded ahead of the market over time. This section compares ILMN with its popular alternatives on both measures, and on beta (how strongly each has moved with the market), over the past 10 years.
- 11 of the 13 popular alternatives had a higher capture ratio (upside capture divided by downside capture) than ILMN's 0.60, led by NTRA, CDNA and DHR.
- NTRA took just 82% of the S&P 500's losses, against 200% for ILMN, while still keeping 169% of its gains.
- Over the past 10 years, ILMN captured 120% of the S&P 500's gains in rising months and 200% of its losses in falling months, with a beta of 1.19. It amplified the market's moves in both directions.
Monthly total returns over the past 10 years, measured against SPY. 100% capture or a beta of 1.00 means moving in line with the S&P 500. Green marks a better figure than ILMN's: more upside, less downside or a higher capture ratio. Sorted by capture ratio.
| Investment | Upside capture | Downside capture | Capture ratio | Beta |
|---|---|---|---|---|
| ILMN This pageIllumina, Inc. | 120% | 200% | 0.60 | 1.19 |
| NTRA Natera, Inc. | 169% | 82% | 2.06 | 1.40 |
| CDNA CareDx, Inc | 186% | 161% | 1.16 | 1.56 |
| DHR Danaher Corporation | 84% | 84% | 1.01 | 0.75 |
| TMO Thermo Fisher Scientific Inc. | 104% | 104% | 1.00 | 0.81 |
| A Agilent Technologies, Inc. | 120% | 141% | 0.85 | 1.13 |
| WAT Waters Corporation | 107% | 139% | 0.77 | 1.01 |
| RVTY Revvity, Inc. | 111% | 146% | 0.76 | 1.10 |
| BRKR Bruker Corporation | 121% | 160% | 0.75 | 1.27 |
| QGEN Qiagen N.V. | 62% | 83% | 0.75 | 0.45 |
| TECH Bio-Techne Corporation | 120% | 162% | 0.74 | 1.23 |
| BIO Bio-Rad Laboratories, Inc. | 104% | 146% | 0.71 | 0.99 |
| NTLA Intellia Therapeutics, Inc. | 139% | 283% | 0.49 | 2.00 |
| PACB Pacific Biosciences of California, Inc. | 76% | 234% | 0.33 | 1.70 |
What diversifies ILMN?
Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions). This section lists large ETFs and stocks whose returns have had a low correlation with ILMN's. Because such investments tend not to fall at the same time, pairing ILMN with them can reduce a portfolio's overall swings.
- Moving a fifth of the money in ILMN into MCK would have cut the portfolio's volatility by 20% over the past 5 years and raised its annual return (-7.0% for ILMN alone, +2.5% for the mix).
- Among large ETFs, LVHI, DXJ and EMLP have moved largely independently of ILMN over the past 5 years, with correlations of 0.20 or lower, and each still earned a positive 5-year return.
- MCK made money in six of the nine calendar years in which ILMN lost money.
Only ETFs with at least $1.0B in assets and stocks worth at least $10B, with a correlation below 0.5 over the past 5 years and a positive return, are included, ranked by Sharpe ratio; funds that hold the same thing are shown once. The year columns are the years in which ILMN lost money. The last two columns show a portfolio that is 80% ILMN and 20% the other investment, rebalanced monthly.
ETFs
| Investment | Correlation | 5Y return | Sharpe | 2025 | 2024 | 2023 | 2022 | 2016 | 2011 | 2008 | 2002 | 2001 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ILMN Illumina, Inc. (this page) | 1.00 | −33.3% | 0.06 | −1.8% | −1.3% | −31.1% | −46.9% | −33.3% | −51.9% | −12.1% | −71.3% | −26.9% | 46.8% | −7.0% |
| LVHI InternationalFranklin International Low Volatility High Dividend Index ETF | 0.20 | +119% | 1.48 | +27.1% | +15.9% | +17.4% | +3.8% | — | — | — | — | — | 37.8% | −1.0% |
| DXJ InternationalWisdomTree Japan Hedged Equity Fund | 0.20 | +225% | 1.34 | +32.8% | +29.8% | +42.0% | +6.0% | +1.1% | −16.1% | −20.8% | — | — | 38.0% | +0.6% |
| EMLP Broad MarketFirst Trust North American Energy Infrastructure Fund | 0.14 | +101% | 1.04 | +9.7% | +33.4% | +8.0% | +10.4% | +29.8% | — | — | — | — | 38.0% | −1.2% |
| HDV Dividend & IncomeiShares Core High Dividend ETF | 0.26 | +83.3% | 1.00 | +11.9% | +14.1% | +1.8% | +7.1% | +15.9% | — | — | — | — | 38.3% | −1.9% |
| SMH TechnologyVanEck Semiconductor ETF | 0.38 | +323% | 0.97 | +49.2% | +39.1% | +73.4% | −33.5% | +35.6% | +6.8% | −44.7% | −47.0% | −14.6% | 40.6% | +2.3% |
| DBEF InternationalXtrackers MSCI EAFE Hedged Equity ETF | 0.35 | +85.0% | 0.96 | +23.1% | +13.4% | +20.1% | −5.1% | +6.3% | — | — | — | — | 38.3% | −1.7% |
| GLD CommoditiesSPDR Gold Shares | 0.02 | +126% | 0.96 | +63.7% | +26.7% | +12.7% | −0.8% | +8.0% | +9.6% | +4.9% | — | — | 37.6% | −0.5% |
| SPMO Broad MarketInvesco S&P 500 Momentum ETF | 0.38 | +136% | 0.93 | +26.6% | +45.8% | +17.6% | −10.4% | +7.4% | — | — | — | — | 39.2% | −0.4% |
Stocks
| Investment | Correlation | 5Y return | Sharpe | 2025 | 2024 | 2023 | 2022 | 2016 | 2011 | 2008 | 2002 | 2001 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ILMN Illumina, Inc. (this page) | 1.00 | −33.3% | 0.06 | −1.8% | −1.3% | −31.1% | −46.9% | −33.3% | −51.9% | −12.1% | −71.3% | −26.9% | 46.8% | −7.0% |
| CAH Medical - DistributionCardinal Health, Inc. | 0.18 | +479% | 1.55 | +76.3% | +19.0% | +34.1% | +54.1% | −17.5% | +8.1% | −39.6% | −8.3% | −2.5% | 38.8% | +2.6% |
| CLS Hardware, Equipment & PartsCelestica Inc. | 0.31 | +3,143% | 1.47 | +220% | +215% | +160% | +1.3% | +7.4% | −24.4% | −20.5% | −65.1% | −25.6% | 42.5% | +12.9% |
| FIX Engineering & ConstructionComfort Systems USA, Inc. | 0.30 | +1,636% | 1.46 | +121% | +107% | +79.6% | +17.0% | +18.3% | −17.0% | −15.2% | −9.4% | +73.7% | 41.0% | +9.7% |
| MCK Medical - DistributionMcKesson Corporation | -0.06 | +413% | 1.44 | +44.5% | +23.7% | +24.1% | +51.8% | −28.3% | +11.8% | −40.4% | −27.2% | +4.9% | 37.4% | +2.5% |
| MPC Oil & Gas Refining & MarketingMarathon Petroleum Corporation | 0.18 | +690% | 1.41 | +19.2% | −4.0% | +30.4% | +86.6% | +0.7% | — | — | — | — | 39.1% | +4.4% |
Common questions
What was ILMN's worst drawdown?
ILMN's deepest decline since it began trading in 2000 was 96.1%, from September 2000 to March 2003. It took about four years from the low to climb back to its old high.
What were ILMN's best and worst years?
Over 25 full calendar years, ILMN's best year was 2006, when it returned 179%. Its worst was 2002, with a return of -71.3%.
Is there a better investment than ILMN?
Among ILMN's popular alternatives, TMO, WAT and A earned more than ILMN with less volatility over the past 5 years. TMO returned 2.9% a year at 27.8% volatility, against a loss of 7.8% a year at 46.9%. Looking beyond its popular alternatives, LLY (pharmaceuticals) and JNJ (pharmaceuticals) earned more than ILMN with less volatility over the past 5 years. LLY returned 40.7% a year at 32.8% volatility, against a loss of 7.8% a year at 46.9%.
Is ILMN more volatile than the S&P 500?
Yes. ILMN's volatility over the past 5 years was 46.9%, 2.7 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, ILMN's return lands within 46.9% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.
What is ILMN's Sharpe ratio?
ILMN's Sharpe ratio over the past 5 years was 0.06, against 0.79 for the S&P 500, so ILMN earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.
How correlated is ILMN with the S&P 500?
Over the past 5 years, ILMN's monthly returns had a correlation of 0.47 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against ILMN instead: the lower it is, the more that option would diversify a ILMN holding.
What are the best alternatives to ILMN?
Of the 21 popular alternatives we compared, two outperformed ILMN in at least 3 of 5 short-term and 2 of 3 long-term timeframes, with dividends reinvested: CDNA and TWST.
Did ILMN outperform the S&P 500?
ILMN finished ahead of the S&P 500 (SPY) in 13 of 25 full calendar years. In 2025, it returned -1.8%, against +17.7% for the index.
How did ILMN do in stock market crashes?
ILMN fell less than the S&P 500 (SPY) in two of the nine major crashes it has traded through, and further in six. The clearest case was the 2022 bear market, when ILMN fell 58.2% and the S&P 500 fell 24.5%.
What diversifies ILMN?
These had a low correlation with ILMN over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.20), DXJ (correlation 0.20) and EMLP (correlation 0.14); among large stocks, CAH (correlation 0.18), CLS (correlation 0.31) and FIX (correlation 0.30). A correlation near zero means the two have moved largely independently.
How we measure
- Short-term periods are 1M, 3M, 6M, YTD, 1Y; long-term periods are 3Y, 5Y, 10Y. An investment outperformed in a period when its total return, with dividends reinvested, was higher than ILMN's. Returns within 0.5 points or 3% of ILMN's, whichever is larger, count as a tie.
- "Qualified" means outperforming in at least 3 of 5 short-term periods and 2 of 3 long-term periods. "All-weather" means outperforming in every long-term period and all but one short-term period.
- Popular alternatives are the funds and stocks most often compared with this one. We include only those that trade today, are not leveraged or inverse, and hold at least $200 million.
- Volatility is the annualized standard deviation of daily returns over 5 years, a measure of how much the price typically swings in a year. The Sharpe ratio is the return above cash for each unit of that volatility.
- A decline, or drawdown, runs from a peak to the lowest close before the next high. The worst decline ever uses all the price history we have; comparisons between funds use the past 10 years so that younger funds are judged on the same stretch.
- Sector overlap is the share of assets two funds hold in the same sectors. Correlation and the mixed-portfolio figures use monthly returns.
- Upside and downside capture follow Morningstar's definition: the compound monthly return in the months the S&P 500 rose (or fell), divided by the S&P 500's compound return in those months. Beta measures how strongly monthly returns have moved with the S&P 500. All three use the same window for every investment.
- Figures are computed from daily adjusted prices and update after each trading day. Past performance does not predict future results.